Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medication Optimization Using Pharmacogenetic Testing and the Genomind Drug Interaction Guide (G-DIG) to Reduce Polypharmacy in a Mental Health Population

NCT03468309 is registered in ClinicalTrials.gov with Seattle Institute for Biomedical and Clinical Research as lead sponsor.

NCT NCT03468309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03468309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medication Optimization Using Pharmacogenetic Testing and the Genomind Drug Interaction Guide (G-DIG) to Reduce Polypharmacy in a Mental Health Population
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Phase
Observational
Overall status
Completed
Start date
January 1, 2018
Completion date
April 17, 2024
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacogenetic testing